Funding/support: This study was partially supported by grants from CONACYT (Project 53231) and SEP-PIFI 3.3 (UAM-X-CA-29).
Antinociceptive Activity of Metamizol Metabolites in a Rat Model of Arthritic Pain
Article first published online: 14 MAY 2013
© 2013 Wiley Periodicals, Inc.
Drug Development Research
Volume 74, Issue 5, pages 332–338, August 2013
How to Cite
López-Muñoz, F. J., Soria-Arteche, O., López, J. R. M., Hurtado y de la Peña, M., García, Ma. C. L., Moreno-Rocha, L. A. and Domínguez-Ramírez, A. M. (2013), Antinociceptive Activity of Metamizol Metabolites in a Rat Model of Arthritic Pain. Drug Dev. Res., 74: 332–338. doi: 10.1002/ddr.21083
Conflict of interest: The authors declare that they have no conflict of interest to disclose.
- Issue published online: 12 JUL 2013
- Article first published online: 14 MAY 2013
- Manuscript Accepted: 16 APR 2013
- Manuscript Received: 15 MAR 2013
- CONACYT. Grant Number: 53231
- SEP-PIFI 3.3. Grant Number: UAM-X-CA-29
- PIFIR model
The aim of the present study was to evaluate the antinociceptive activity of the main metamizol (MET) metabolites, 4-methylaminoantipyrine (MAA), 4-aminoantipyrine (AA), 4-formylaminoantipyrine (FAA), and 4-acetylaminoantipyrine (AAA) using the “pain-induced functional impairment in rat” model (PIFIR model). The antinociceptive efficacies of MAA and AA were 288.3% h and 281.1% h, respectively, close to the efficacy of MET (333.80% h). The effective dose to attain 50% of the maximum response (ED50) values for MET, MAA and AA were 126.1, 124.9, and 110.7 mg/kg, respectively. FAA and AAA were essentially inactive in this experimental model. Part of the antinociceptive effect showed by MET in this study might be attributed to the effect of the metabolites MAA and AA on cyclooxygenases COX-1 and COX-2 activity.